Stock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential

Stock Track

Mar 02

4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.

The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.

The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1154718745"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154718745\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154718745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154718745","market":"us","top_or_hot":-1,"title":"Stock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential","media":"Stock Track","content":"<p>4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.</p><p>The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.</p><p>The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | 4DMedical Soars 5.00% Intraday on FDA Approval and US$1.1 Billion Market Potential\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-02 08:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.</p><p>The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.</p><p>The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"4DX.AU","symbol_name":"4DMEDICAL LTD","start_time":0,"source_url":"","article_id":"1154718745","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154718745","pubTimestamp":1772410109,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.The significant price movement appears to be...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"4DX.AU":"4DMEDICAL LTD"},"translate_title":"个股追踪|4DMedical盘中大涨5.00%获FDA批准及11亿美元市场潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"4DX.AU":1},"content_text":"4DMedical Limited's stock surged 5.00% during Monday's intraday trading session, reflecting heightened investor interest in the medical imaging company.The significant price movement appears to be driven by recent developments regarding the company's CT:VQ imaging platform. According to recent reports, 4DMedical has received FDA 510(k) clearance and CMS reimbursement approval for its CT:VQ product, positioning it for commercial deployment in the United States.The company has highlighted an initial addressable U.S. market exceeding US$1.10 billion annually for the newly approved CT:VQ imaging technology. This substantial market opportunity, combined with regulatory clearance, has likely contributed to investor optimism about the company's growth prospects despite recent financial results showing continued investment in product development and commercialization.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}